The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
The presidential candidate has called for the FBI to fully explain the new emails that have come to light.
The American Airlines plane caught fire at Chicago O'Hare airport, prompting an evacuation of the plane.
As the number of people sleeping rough in England increases significantly, a new bill aimed at cutting homeless has passed a second reading.